A key highlight of the quarter came right at the end when Nevro won FDA approval for HFX AdaptiveAI, an AI-powered, ...

Nevro's HFX iQ spinal cord stimulator earned the European Union's CE mark, the company said Nov. 12.

Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)EINDHOVEN, ...

The global spinal cord stimulators market is on a robust growth trajectory, poised to reach an impressive valuation of USD 5,441.4 million by 2033. Currently valued at USD 2,702.7 million in 2023, the ...